The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | SCLC hyperprogression with nivolumab

Name: SCLC hyperprogression with nivolumab
Uploaded: 2019-09-29T00:00:00.000Z
Duration: 1 min 49 s
Description: Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses an analysis of tumor hyperprogression (HP) with nivolumab in small- cell lung cancer (SCLC) randomized, placebo-controlled trials. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Martin Reck • 29 Sep 2019

ESMO 2019

Lung Cancer Small Cell Lung Cancer Nivolumab

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses an analysis of tumor hyperprogression (HP) with nivolumab in small- cell lung cancer (SCLC) randomized, placebo-controlled trials. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.